China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A

SSSE:600062
15.32
CNY
-0.04
(-0.26%)
1.55EPS
10.69P/E
16.87BMarket Cap
Mar 19Next Earn
China Resources Double-Crane Pharmaceutical Co., Ltd. Class A
SSE:600062
(Shanghai Stock Exchange)

Recent

price

15.32

P/E

ratio

10.69

div

yld

3.64%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
6.52
7.75
8.49
8.3
4.94
4.93
5.27
6.16
7.88
8.99
8.15
8.73
9.3
11.04
10.91
10.65
10.45
Revenue per Share
0.63
0.64
0.75
1.06
0.71
0.63
0.68
0.81
0.93
1.01
0.96
0.9
1.14
1.63
1.58
1.59
1.52
Basic EPS, GAAP
0.23
0.21
0.21
0.4
0.73
0.51
0.63
0.99
1.19
1.15
0.97
0.81
0.86
1.22
1.16
0.84
- -
Free Cash Flow per Basic Share
0.18
0.19
0.3
0.26
0.64
- -
0.18
0.19
0.09
0.29
0.31
0.29
0.77
0.3
1.44
0.69
0.56
Dividend per Share
4.73
5.17
5.65
6.48
7.47
5.85
6.41
7.15
7.51
8.25
8.89
9.49
10.12
11.75
10.02
11.2
12.01
Book Value per Share
4.44
4.72
5.1
5.88
6.82
4.54
5.04
5.12
5.22
5.87
6.55
6.92
6.9
8.41
6.79
7.72
8.58
Tangible Book Value per Share
823
823
823
823
1,043
1,043
1,043
1,043
1,043
1,043
1,043
1,043
1,036
1,024
1,028
1,033
1,032
Basic Weighted Avg Shares
5,367
6,383
6,989
6,835
5,153
5,138
5,495
6,422
8,225
9,381
8,504
9,112
9,625
11,310
11,212
11,001
10,784
Sales/Revenue/Turnover
11.3
10.13
10.21
11.67
16.09
14.5
15.61
16.75
14.34
13.91
14.55
12.11
13.84
15.92
15.08
16.3
14.5
Operating Margin (%)
158
176
215
268
268
270
315
337
345
360
374
467
562
690
756
788
- -
Depreciation Expense
520
529
614
871
737
661
714
843
969
1,055
1,005
936
1,180
1,670
1,628
1,647
1,568
Net Income, GAAP
13.6
21.4
17.33
18.12
16.15
17.59
18.48
16.3
16.44
15.48
16.59
13.29
14.03
14.08
11.57
11.91
11.69
Effective Tax Rate (%)
9.69
8.29
8.79
12.74
14.29
12.87
13
13.12
11.78
11.25
11.82
10.27
12.26
14.77
14.52
14.97
14.54
Profit Margin (%)
1,995
2,045
2,209
2,802
3,286
2,655
3,291
3,571
3,007
3,697
4,133
4,792
4,556
4,602
3,474
4,085
5,457
Working Capital
13
- -
- -
- -
1
11
- -
2
7
1
122
35
233
30
1,112
1,051
1,759
LT Debt
3,959
4,343
4,707
5,336
6,179
6,434
7,038
7,849
7,909
8,677
9,358
10,477
11,325
12,899
11,112
12,500
13,364
Total Equity
12.96
11.54
12.42
15.95
11.88
9.88
10.15
11.86
12.45
12.64
11.17
9.77
10.99
12.96
12.67
12.52
- -
Return on Invested Capital (%)
12.9
11.65
12.69
16.81
12.6
10.47
10.23
10.79
12.05
12.57
10.97
9.08
10.26
13.63
12.69
12.61
- -
Return on Capital (%)
14.11
12.98
13.79
17.44
12.83
10.78
11.17
11.92
12.66
12.83
11.24
9.76
11.53
14.67
14.39
14.94
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
126
166
136
LT Borrowings
1,542
1,011
1,736
LT Finance Leases
20
22
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,039
1,039
1,039
Market Capitalization
19,286
16,659
16,866

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,053
8,145
9,028
Cash, Cash Equivalents & STI
3,071
2,774
2,120
Accounts Receivable, Net
2,415
2,547
2,427
Inventories
1,496
1,538
1,612
Total Current Liabilities
3,011
3,764
3,571
Payables & Accruals
- -
- -
- -
ST Debt
126
166
136
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.18%
6.52%
12.5%
Free Cash Flow
7.87%
-0.55%
-26.75%
Net Income, GAAP
10.46%
11.88%
1.18%
Sales/Revenue/Turnover
8.41%
5.51%
-1.88%
Total Cash Common Dividend
602.03%
85.98%
-51.59%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,145
3,094
2,619
2,663
11,212
2025
3,079
2,663
- -
2,718
11,001
2026
2,807
2,809
2,451
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.5
0.61
0.34
0.22
1.58
2025
0.49
0.45
- -
0.29
1.59
2026
0.47
0.45
0.31
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.98
0.98
0.26
0.2
1.44
2025
0.01
0.2
- -
0.11
0.69
2026
0.01
0.06
0.38
- -
- -
Business
China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SS) is a leading China-based pharmaceutical company primarily engaged in the research, development, production, and sale of innovative chemical drugs and formulations; its core businesses span three key segments including chronic disease medications for blood pressure, lipid, and glucose control such as compound reserpine amphoteridine tablets (No. 0), gliquinone tablets, amlodipine benzenesulfonate tablets (diazepine), valsartan capsules (Hoetsu), valsartan hydrochlorothiazide tablets (fujiyue), irbesartan dispersible tablets, nifedipine sustained-release tablets (II) (beciline), and nifedipine controlled-release tablets (betsicon); specialist drugs targeting cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia, and respiratory areas; and infusion products encompassing basic infusion, therapeutic infusion, and nutritional infusions like citicoline sodium tablets (Novartis); the company also produces active pharmaceutical ingredients (APIs) and pharmaceutical equipment. Founded in 1939 and headquartered at No. 1, Lize East 2nd Road, Beijing, China, it operates 24 subsidiaries with approximately 13,414 employees, serving primarily the domestic market across major therapeutic categories such as anti-influenza, antihypertensives, antibiotics, oncology, anti-infection, and more, while maintaining strong channel coverage, cost control, and internationalization capabilities as a subsidiary of Beijing Pharmaceutical Group Co., Ltd. In recent developments, the company completed the acquisition of 100% stake in China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group for CNY 3.1 billion in March 2024, consolidating its chemical drugs business and enhancing synergies; it reported 2024 revenue of RMB 11.21 billion and net profit of RMB 1.65 billion, reflecting robust growth in its formulation, chronic disease, specialty, and infusion segments; additionally, it continues to invest over 10% of annual revenue in R&D, supporting new drug innovation and market expansion.